CA-VISA-INC.
23.6.2020 06:02:08 CEST | Business Wire | Press release
Visa Inc. (NYSE:V) today announced that the company has now issued more than 1 billion tokens worldwide through Visa Token Service (VTS), marking a major milestone in its proprietary offering to help accelerate eCommerce innovation and make payments more secure. Visa Token Service replaces a cardholder’s 16-digit Visa account number with a secure token that protects the underlying card number from fraudsters.
The rapid adoption of Visa’s tokenization technology comes as the world’s massive shift to digital has changed the way we live, work and buy, with 90% of shoppers hesitant to shop in stores and 45% claiming online shopping is now a necessity1 . With digital buyers expected to hit 2.1 billion worldwide by 20212 , Visa’s tokenization technology as well as its click to pay experience play a vital role in strengthening digital payment security globally, which is more critical now than ever before.
With more merchants and retailers adopting tokenization technology, VTS is scaling and accelerating its credential-on-file (COF) tokenization efforts. Today, there are over 13,000 merchants transacting with Visa COF tokens3 . There are also over 8,200 issuers enabled on Visa Token Service from 150 markets.
“The world’s massive shift to digital underscores the need for easy and secure digital commerce, which is why we’ve seen such an increase in the number of tokens issued by Visa Token Service,” said Ansar Ansari, senior vice president, digital payment products, Visa. “In the last 12 months alone, Visa has issued more than 680 Million tokens, and we’re excited to be expanding our capabilities even further so we can secure even more types of digital transactions – even those without a 16-digit Visa credential.”
The Next Billion Tokens – Visa Takes Tokenization From the Card to Cloud
Looking ahead, Visa is launching new and evolved solutions to minimize operational risks around data protection for merchants and mobile carriers, reducing unnecessary steps and friction for consumers. These advancements enable Visa to implement the latest industry-leading security measures that can be applied at both the network and financial institution level.
- Token ID Expands Tokenization Capabilities Beyond the Card: Visa is unveiling the rebrand of its recently acquired Rambus Payments token services business, to Token ID – A Visa Solution. Token ID expands Visa’s tokenization capabilities beyond card-based payments on the Visa network to those on domestic card networks, account-based and real-time payments. When working in collaboration with Visa Token Service, Token ID will help clients scale fraud-reduction, secure payment solutions achieved by tokenization technology, while helping Visa expand its tokenization services to new markets with specific localization requirements such as Turkey and China.
- Token Management Service by CyberSource: Token Management Service by CyberSource centralizes and simplifies token management to secure customer payment data, improve payment conversions and eases PCI compliance implications. It links tokens across service providers, all payment types and channels for merchants, acquirers and technology platforms. It creates one unified token identifier – a token-of-tokens – to centralize and orchestrate management of all payment instruments, including cards, bank accounts and local payment schemes. The unified token identifier generated by CyberSource protects sensitive customer payment data and provides a 360-degree view of the customer across payment channels, merchant rewards, and loyalty programs.
- Cloud Tokens: As consumers expand their use of devices for online shopping, Visa has enabled a new, cloud-based system that allows more flexibility than binding tokens to a single device. The Visa Cloud Token Framework enables eCommerce and card-on-file tokens provisioned to the consumers’ account to be bound to multiple trusted devices. Cloud Tokens are available globally but launched first in LAC. Specifically, Brazilian consumers are the first in the world to use the new Visa Cloud Token technology to help enable secure payments on WhatsApp.
The 1 billion tokens milestone is another key moment in this drive to innovate, and comes on the heels of Visa naming 28 new partners to VTS as COF token requestors, set to make digital transactions more secure by tokenizing both one-time and recurring payments made with Visa credentials.
For more information about Visa Token Service, visit here .
1
Retail Systems Research Consumer Report: March 2020
2
Statista, Number of digital buyers worldwide from 2014 to 2021
3
VisaNet merchant data based on tokenized transactions processed between Jan. 2019 and June 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005749/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
